Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,146
- Phase 21,063
- Phase 1820
- Phase 1/Phase 2442
- Phase 3425
- Phase 4238
- Phase 2/Phase 396
Top conditions
- Multiple Sclerosis343
- Multiple Myeloma332
- Asthma194
- Lymphoma183
- Rheumatoid Arthritis140
- Type 1 Diabetes134
- Atopic Dermatitis130
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections113
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Type 1 Diabetes Mellitus63
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)73
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals60
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California494
- Maryland195
- Alabama176
- Florida145
- Arizona141
- New York122
- Massachusetts119
- Texas118
- Illinois81
- Colorado76
Recruiting studies6,230 total
- NCT07454226Recruiting
Drug combo for Ph-like acute lymphoblastic leukemia
This trial tests a combination of targeted drugs (ABL/JAK inhibitors) with chemotherapy and venetoclax for people with a type of leukemia called Ph-like ALL. It aims to see if this treatment is safe and effective.
Tianjin, Tianjin MunicipalityAges 14–60 - NCT07454382RecruitingPhase 2
Study of elranatamab and cyclophosphamide for multiple myeloma
This trial studies a new medicine called elranatamab combined with the chemotherapy drug cyclophosphamide for people with multiple myeloma that has returned or not responded to prior treatments. It may be a good option if you have aggressive or high-risk myeloma.
Basking Ridge, New JerseyAges 18 years+ - NCT07455578RecruitingPhase 1
Study of S-4321 for people with autoimmune or immune diseases
This trial tests a new medicine, S-4321, for people with various autoimmune conditions like rheumatoid arthritis, psoriasis, eczema, or lupus. It aims to see if the drug is safe and can help control the overactive immune system.
Charlestown, New South WalesAges 18–75 - NCT07456371RecruitingPhase 1
PIC1 injection for relapsed or refractory B-cell lymphoma
This trial tests a new treatment called PIC1 for people with certain types of B-cell lymphoma that have come back after treatment or stopped responding. PIC1 is a type of immunotherapy that helps your immune system attack the cancer cells.
Wuhan, HubeiAges 18–75 - NCT07460362RecruitingPhase 2
Glofitamab and lenalidomide for high-risk mantle cell lymphoma
This trial tests a combination of two drugs, glofitamab and lenalidomide, for people with mantle cell lymphoma that has come back or not responded to treatment. It's for those with high-risk features, like a fast-growing lymphoma or resistance to previous therapies.
Beijing, Beijing MunicipalityAges 18–80 - NCT07461805Recruiting
Understanding type 1 diabetes with AI and glucose data
This study uses artificial intelligence to analyze glucose monitor data from people with type 1 diabetes. The goal is to find patterns that could improve care and treatment.
Barcelona, BarcelonaAges 18 years+ - NCT07461896Recruiting
Nerve function study in Charcot-Marie-Tooth and related neuropathies
This study looks at how nerves work and their structure in people with Charcot-Marie-Tooth disease, CIDP, or anti-MAG neuropathy. It may help doctors better understand these conditions.
MilanAges 18 years+ - NCT07463937Recruiting
Study of Methotrexate Injections in Rheumatoid Arthritis
This study looks at how well methotrexate injections work in people with rheumatoid arthritis. It is designed for patients who are starting or changing to this type of methotrexate treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07466823Recruiting
Spasticity Patterns and Quality of Life in MS
This study looks at patterns of muscle stiffness (spasticity) in people with multiple sclerosis and how these patterns affect daily life and well-being. It aims to better understand the link between spasticity and quality of life.
IstanbulAges 18 years+ - NCT07468136RecruitingPhase 1/Phase 2
Retifanlimab with or without DFMO for progressive high-grade gliomas
This study tests a combination of two drugs—retifanlimab (an immunotherapy that helps your immune system fight cancer) and DFMO (a medicine that may stop tumor growth)—in people with high-grade brain tumors that are growing. Participants will receive these treatments before and after their planned surgery.
Rochester, MinnesotaAges 18 years+ - NCT07468474Recruiting
Finding Type 1 Diabetes Risk and Offering Education
This study is designed to help identify and monitor people at high risk for type 1 diabetes. It involves education and regular check-ups to better understand and manage the condition.
Beijing, Beijing MunicipalityAges 4 years+ - NCT07470151Recruiting
Study of EVM18001 for hard-to-treat autoimmune diseases
This trial tests a new treatment, EVM18001, for people with lupus, myasthenia gravis, or systemic sclerosis that hasn't improved with standard therapies. It aims to see if this therapy can help control the disease.
Wuhan, HubeiAges 18–70 - NCT07470593Recruiting
Monitoring glucose to detect early pancreatic islet graft loss
This study uses a continuous glucose monitor (CGM) to watch for early signs that a transplanted pancreatic islet graft may be losing function. The goal is to catch problems sooner and help keep the transplant working well.
StrasbourgAges 18 years+ - NCT07470996Recruiting
T-cell lymphoma treatment after first therapy fails
This trial is for people with certain T-cell lymphomas that did not respond or got worse after initial chemotherapy. It offers a personalized treatment plan, possibly including a stem cell transplant, based on how your disease behaved after first-line therapy.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07471789RecruitingPhase 1/Phase 2
CART84 therapy for AML and T-ALL leukemia
This trial tests a new treatment called CART84 (GYA01) for patients with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) that has come back or not responded to standard treatments. CART84 uses specially engineered immune cells to target and destroy leukemia cells that have a protein called CD84 on their surface.
Barcelona, BarcelonaAges 18 years+ - NCT07472738Recruiting
Studying treatable traits in chronic airway diseases
This trial is studying people with chronic lung conditions, like COPD or asthma, to find treatable traits. It also includes healthy volunteers for comparison, to better understand what makes these diseases different and how to personalize treatment.
Beijing, Beijing MunicipalityAges 20–75 - NCT07472972Recruiting
Personalized risk tracking for CD19 CAR T therapy
This study follows patients with relapsed or hard-to-treat B-cell lymphoma who are receiving CD19-directed CAR T cell therapy. Researchers collect blood and tissue samples to better understand each patient's unique risk profile, aiming to improve how the treatment is monitored and managed.
Zurich, Canton of ZurichAges Any age - NCT07473167RecruitingPhase 1/Phase 2
Study of TC011 for large B-cell lymphoma that has not responded to treatment
This trial tests whether the experimental drug TC011 can help adults with a type of B-cell lymphoma that has come back or stopped responding after at least two rounds of chemotherapy. The study checks for safety and whether the treatment can shrink tumors.
Seoul, SeoulAges 19 years+ - NCT07474935Recruiting
Real-world stroke treatment device registry
This trial collects information about the use of a specific stroke treatment device in real-world medical practice. It helps researchers see how well this device works for a wide range of patients, not just those in strict study conditions.
BrestAges Any age - NCT07477015Recruiting
Study to find new antibodies in autoimmune encephalitis
This research study looks for new markers in the blood of people with autoimmune encephalitis (a condition where the immune system attacks the brain). It aims to better understand what causes the disease and find new ways to diagnose it.
Rome, RMAges 18 years+ - NCT07477587RecruitingPhase 1
Comparing two myeloma treatments for new patients
This trial tests a new drug combination (HLX15-SC) against an approved treatment (DARZALEX FASPRO) along with lenalidomide and dexamethasone for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant.
Springdale, ArkansasAges 18 years+ - NCT07477639RecruitingPhase 1/Phase 2
Testing TRX319 for worsening multiple sclerosis
This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.
Kansas City, KansasAges 18–65 - NCT07477912RecruitingPhase 1/Phase 2
BCMA-targeting CAR-T for relapsed/refractory multiple myeloma
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
MinskAges 18 years+ - NCT07478172Recruiting
Electrical muscle stimulation exercise for neuromuscular disease
This study tests whether whole-body electrical muscle stimulation (using small electrodes on the skin) can help adults with certain neuromuscular diseases exercise and improve muscle strength. It may be an option if you can stand for about 15 minutes at a time and have some muscle strength left.
Columbia, MissouriAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,786 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.